Direct compression of enalapril maleate veterinary tablets for canine and feline cardiology is constrained by low unit dose and the API’s tendency to pick up moisture at RH above 55%. The active pharmaceutical ingredient is incorporated at 0.3% w/w to 5.0% w/w across label strengths of 1 mg, 2.5 mg, 5 mg, 10 mg, and 20 mg. A direct compression vehicle containing microcrystalline cellulose, lactose monohydrate, crospovidone, and magnesium stearate is processed in a bin blender at 25 rpm for 15 min after geometric dilution of the API with an equal mass of carrier. A second blending phase follows addition of magnesium stearate at 0.5% w/w for 5 min because extended lubrication above 10 min can reduce tablet tensile strength and slow dissolution. Blend uniformity is verified by stratified sampling at ten positions with three replicate HPLC determinations per sample. The acceptance value is calculated under USP <905> and Ph. Eur. 2.9.40. Compression is performed on a rotary tablet press at 5 kN to 12 kN force and speeds up to 50,000 tablets/h. Tablet hardness is maintained at 40 N to 60 N, with friability not more than 0.8% after 100 revolutions per Ph. Eur. 2.9.7. Compression force above 14 kN is not recommended because elastic recovery of microcrystalline cellulose at press speeds above 50,000 tablets/h produces capping and edge chipping. When direct compression blend RSD exceeds 3.0% or API agglomerates are retained above 150 μm, wet granulation is selected. In that route, a high-shear granulator is operated with impeller speed 300 rpm to 400 rpm and chopper speed 1500 rpm to 2000 rpm. Purified water or a 60:40 water:ethanol granulating fluid is added at 6% w/w to 10% w/w. The wet mass is dried in a fluid bed at inlet air temperature 45 °C to a loss-on-drying endpoint not more than 2.0% per Ph. Eur. 2.2.32. Finished tablets are packaged in PVC/PVDC-aluminium blisters with silica gel desiccant because open exposure above 60% RH for more than 4 h has been observed to increase moisture uptake and reduce blend flow in subsequent processing. Dissolution is monitored by USP <711> or Ph. Eur. 2.9.3 using the enalapril maleate tablet monograph conditions and the Q value from the approved veterinary product dossier. Alkaline fillers such as dibasic calcium phosphate dihydrate are avoided because local surface pH above 6.0 promotes hydrolytic degradation and diketopiperazine formation.

Does Terminal Steam Sterilization Accelerate Diketopiperazine Formation in Enalapril Maleate Veterinary Injections?

Aqueous injectable solutions of enalapril maleate are prepared at 1 mg/mL to 2 mg/mL in citrate buffer at pH 3.2 to 4.0. The maleate salt acidifies purified water to pH 2.4 to 2.8 before buffer addition; pH adjustment using sodium hydroxide is performed slowly with cooling because local alkalinity above pH 6.0 accelerates ester hydrolysis to enalaprilat and intramolecular cyclization to diketopiperazine. Aseptic filtration through a 0.22 μm PVDF or polyethersulfone membrane is preferred over terminal steam sterilization because stress studies show that exposure at 121 °C for 15 min increases total degradation products in unbuffered or weakly buffered systems. If terminal sterilization is unavoidable, the solution is blanketed with nitrogen and the headspace oxygen content is maintained below 2% by volume. Published data for this specific configuration is limited; each sterilization cycle must be validated to keep enalaprilat and diketopiperazine below the acceptance limits established under VICH GL2. Endotoxin control follows USP <85> with a limit calculated from the K/M equation using K = 2.5 EU/kg and the maximum dose administered to the smallest labelled patient weight. Particulate matter is controlled under USP <788> for small-volume injections: not more than 6,000 particles ≥ 10 μm and 600 particles ≥ 25 μm per container. The solution is filled into Type I borosilicate glass vials with bromobutyl rubber stoppers and stored at 2 °C to 8 °C protected from light. Sodium chloride or mannitol is used for tonicity adjustment because sodium bicarbonate and other alkaline tonicity modifiers raise pH into the instability zone above pH 5.0. Freeze-thaw cycling is avoided because pH drift above 5.0 during thawing can cause precipitation of the diacid form. Processing water for injection is used throughout to avoid endotoxin burdens that cannot be removed by filtration alone.

Capsule filling for feline low-dose titration: particle size, excipient flow, and hard gelatin shell moisture transfer.

Capsule filling of enalapril maleate for feline cardiology uses hard gelatin or hydroxypropyl methylcellulose capsules in sizes 3, 4, and 5, with total fill weights from 60 mg to 180 mg and API content from 0.25 mg to 5 mg. The low drug load requires pre-blending with lactose monohydrate or microcrystalline cellulose in a low-shear V-blender at 50% of nominal volume. Powder flow is characterized under USP <1174>; enalapril maleate often presents an angle of repose above 40°, so colloidal silicon dioxide is added at 0.25% w/w to 0.5% w/w and sodium stearyl fumarate is used as lubricant at 0.5% w/w to 1.0% w/w. Automatic capsule machines operate at fill speeds below 10,000 capsules/h because higher speeds increase fill weight variability for low-dose powder beds. Content uniformity is tested by USP <905> or Ph. Eur. 2.9.40, and dissolution is tested by USP <711> or Ph. Eur. 2.9.3. Empty capsule shells are conditioned at 35% RH to 45% RH; below this range shells become brittle, while above 55% RH the gelatin shell softens and the API-bearing blend may gain moisture. Storage in PVC/PVDC-aluminium blisters or HDPE bottles with desiccant is required. The use of magnesium stearate is limited to not more than 0.75% w/w because higher levels delay dissolution in low-dose capsule formulations. Alkaline diluents are avoided for the same pH-related degradation reasons described for tablet manufacture.

Palatable oral powder packets for owner administration in cats and small dogs are prepared at enalapril maleate concentrations of 1 mg/g to 10 mg/g in an acid-stable carrier of maltodextrin or lactose monohydrate. The powder is intended for reconstitution or direct oral administration in food, so flavour masking must not rely on alkaline agents such as disodium phosphate or sodium bicarbonate; these raise local pH above 6.0 and accelerate degradation. Geometric dilution is performed from a 1:1 preblend to a final mix in a V-blender at 25 rpm for 20 min. Stratified sampling at ten locations with triplicate HPLC injections yields a blend RSD of not more than 5.0%. Filling into foil/polyethylene sachets uses a vertical form-fill-seal line with moisture vapour transmission rate below 0.1 g/m²/day at 38 °C and 90% RH. The finished powder is controlled for loss on drying not more than 2.0% per Ph. Eur. 2.2.32. Stability samples are placed at 25 °C ± 2 °C / 60% RH ± 5% RH and accelerated at 40 °C ± 2 °C / 75% RH ± 5% RH under VICH GL1. Humidity excursions above 60% RH on the manufacturing floor must be limited to less than 4 h because enalapril maleate picks up surface moisture and begins to cake in bulk containers. Particle size of the carrier is matched to the API to reduce segregation; carrier particle size is preferably below 300 μm with not more than 15% fines below 75 μm. The powder is dispensed with a graduated scoop or unit-dose cup marked in 0.25 mg increments to permit low-dose titration.

When wet granulation is required for sprinkle granules, the binder level controls both granule hardness and degradation profile.

Wet granulation of enalapril maleate for sprinkle granules is implemented only when direct powder blends fail flow requirements or when dust control during sachet filling is unacceptable. A hydroalcoholic granulating fluid containing 5% w/w hypromellose E5 in 60:40 water:ethanol is added at 8% w/w to 12% w/w to a high-shear granulator. Impeller speed is set at 250 rpm to 350 rpm and chopper speed at 1500 rpm to 2000 rpm for 3 min to 5 min. The granulation endpoint corresponds to a wet mass loss-on-drying of 12% to 15%. Drying is performed in a fluid bed at inlet air temperature 40 °C to 50 °C; product temperature must not exceed 45 °C because higher temperatures accelerate diketopiperazine formation. The dried granules are screened to 150 μm to 710 μm. Fines below 75 μm are recycled into the next granulation at not more than 20% of the dry mass to avoid density segregation in the final sachet fill. Granule hardness is not adjusted by increasing binder level above 15% w/w because the resulting dense granules delay dissolution in oral administration. The finished granules are filled into stick packs or sachets at 0.5 mg to 5 mg unit dose and tested for content uniformity under Ph. Eur. 2.9.40. Dissolution is monitored by USP <711> or Ph. Eur. 2.9.3 using a discriminating aqueous medium. Storage follows VICH GL1 long-term and accelerated conditions; moisture-impermeable packaging with desiccant is required because dried granules regain moisture if exposed above 55% RH.

Premix dilution and carryover control in companion animal medicated feed operations.

Enalapril maleate premixes intended for companion animal feed admixtures are prepared by stepwise geometric dilution with ground corn or microcrystalline cellulose from a concentrate of 10 g/kg to target final feed concentrations of 10 mg/kg to 200 mg/kg. Regulatory boundary is critical: no maximum residue limit for enalapril is listed in Table 1 of Regulation (EU) No 37/2010, and the compound is not approved for use in food-producing animals in the United States. Premix operations must therefore remain within companion animal compounding pathways and comply with 21 CFR 225 current good manufacturing practice for medicated feeds, where applicable under state or federal veterinary compounding rules. Each tenfold dilution step is mixed in a ribbon blender at 60% of nominal capacity for 5 min at 30 rpm. After mixing, samples are taken at 12 points with a sampling thief and analyzed by HPLC; acceptance is not more than 5.0% RSD. Carryover control uses a flush of 5 kg ground corn followed by swab sampling of contact surfaces. The limit for residual enalapril maleate is set at 0.1% of the lowest labelled dose in the subsequent non-medicated batch. Alkaline carriers such as limestone or calcium carbonate are not used because surface pH above 6.0 promotes degradation. Molasses-based liquid carriers are avoided because free water accelerates hydrolysis. Open-trough storage at 25 °C and 60% RH is limited to 90 days unless stability data under VICH GL1 support a longer in-use period. Weighing and blending areas are segregated to prevent cross-contamination with food-producing animal feed lines.

For extemporaneous liquid formulations used in small animal cardiology, enalapril maleate is dissolved in purified water at 1 mg/mL to 5 mg/mL and buffered with citric acid/sodium citrate to pH 3.2 to 4.0. The maleate salt alone acidifies the vehicle to pH 2.4 to 2.8; complete dissolution is confirmed before buffer addition because pH gradients during mixing alter local solubility. Sodium benzoate or methyl paraben is used as preservative, and preservative efficacy is evaluated under Ph. Eur. 5.1.3 or USP <51>. Sorbitol at 70% is acceptable as a sweetener only if preservative efficacy is confirmed; alkaline syrups and sodium bicarbonate are excluded because they raise pH above 5.0 and accelerate hydrolysis and diketopiperazine formation. The solution is packaged in amber Type III glass bottles with child-resistant closures and an oral dosing syringe graduated in 0.1 mL increments. Storage at 2 °C to 8 °C is specified; at room temperature the beyond-use date is typically limited to 30 days because pH drift above 5.0 can occur in poorly buffered vehicles. Stability-indicating HPLC methods quantify enalaprilat and diketopiperazine under VICH GL2; retention times and peak purity are established with forced degradation samples at 40 °C and 75% RH. Freeze-thaw cycles are not recommended because crystallization or local supersaturation may occur. The solution should not be mixed with alkaline liquid feed supplements, milk replacers, or bicarbonate-containing oral rehydration solutions at the time of dosing unless compatibility has been demonstrated by pH measurement and assay.